Clinigen shares soar after $210m Novartis cancer drug deal

pharmafile | February 13, 2019 | News story | Research and Development Cancer, Clinigen, Novartis, Proleukin, UK, US, oncology 

British company Clinigen has bought the rights to sell Novartis’ cancer drug Proleukin in the United States in a deal worth $210 million.

Clinigen, a growing speciality pharma group, already sells Proleukin outside of the US. Proleukin is used to treat metastatic kidney cancer and metastatic melanoma.

Clinigen will pay an initial sum of $120 million for the US rights alongside a further $60 million which will be differed for a year. The remaining $30 million will be paid dependent on the drug reaching certain sales milestones.

Proleukin generated $60 million in US sales last year. Clinigen believe the drug could become an integral component of cancer combination therapies.    

“This highly earnings enhancing acquisition of US rights to Proleukin is significant to the whole group not just the commercial medicines division,” said chief executive Shaun Chilton.

Shares in the firm were up by nearly 15% on announcement of the news.

Louis Goss

Related Content


BioInvent and Transgene announce positive phase 1a solid tumour trial data

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from …


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

FDA announces acceptance and priority review of NDA for LUMISIGHT imagining agent for breast cancer

Lumicell has announced that the US Food and Drug Administration (FDA) has accepted and granted …

Latest content